Open AccessA Systemic Review of Clinical Trial of 2 -deoxyglucose in Treating Covid-19
Author(s) -
A.Afajal. A.R.Sheikh,
Vaishnavi Padole,
Sachin More,
Sachin Mendhi
Publication year - 2021
Publication title -
international journal of pharmaceutical sciences review and research
Language(s) - English
Resource type - Journals
ISSN - 0976-044X
DOI - 10.47583/ijpsrr.2021.v70i02.014
Subject(s) - nitazoxanide , lopinavir , ritonavir , medicine , pharmacology , hydroxychloroquine , drug repositioning , cytokine storm , pandemic , approved drug , drug , fluvoxamine , chloroquine , covid-19 , virology , malaria , viral load , human immunodeficiency virus (hiv) , immunology , antiretroviral therapy , fluoxetine , receptor , disease , infectious disease (medical specialty) , serotonin
After sudden outbreak of covid-19 pandemic, to overcome this chaotic situation many drug therapies have been used which includesChloroquine, Hydroxychloroquine (Antimalarial), Lopinavir and Ritonavir (antiviral), Nafamostat (Sirin protease inhibitor), Famotidine(Antihistamines), Nitazoxanide (Anti-infective), Evermectin (Anti-parasitic), Corticosteroids, Tocilizumab & Sarilumab (Inflammatorycytokine), Fluvoxamine(Anti-depressants), but due to prominent effect of 2-DG it has been extensively used against SARS-CoV-2. It isa glucose molecule which was approved for the emergency treatment in covid-19 pandemic against SARS-CoV-2 by inhibitingglycolysis-The energetic cycle. It shows more highlighting effect with combinational approach. This drug was sanctioned by DrugController General of India (DCGI) and has been developed by Institute of medicine and Allied Sciences (INMAS), a lab of DefenceResearch and Development Organization (DRDO), together with Dr Reddy’s Laboratories (DRL), Hyderabad.